On Jan. 05, Leschly Nick divested U.S. $469,783 in shares of bluebird bio Inc.. The Pres, CEO sold 10,428 shares at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 255,962 shares worth around $12.42 million at present.
Another 949 shares were sold by Baird William D III, for more than $42,756 in total proceeds. The CFO dumped the shares at a price of $45.05 and the insider now owns almost 22,797 shares.
That same day, Finger Alison Cecily sold 1,854 shares. The Chief Commercial Officer divested U.S. $83,525 in shares of bluebird bio Inc. at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 25,103 shares worth around $1218499.62 at present.
Davidson David sold 3,215 shares. The Chief Medical Officer divested U.S. $144,841 in shares of bluebird bio Inc. at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 36,361 shares worth around $1764962.94 at present.
Cole Jason sold 2,401 shares. The COO and divested U.S. $108,169 in shares of bluebird bio Inc. at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 32,823 shares worth around $1593228.42 at present.
Smith-Farrell Joanne sold 1,329 shares. The COO, Oncology divested U.S. $59,872 in shares of bluebird bio Inc. at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 20,609 shares worth around $1000360.86 at present.
Gregory Philip D sold 2,799 shares. The Chief Scientific Officer divested U.S. $126,100 in shares of bluebird bio Inc. at a price per share of $45.05. The transaction decreased this specific insider’s holdings to 33,007 shares worth around $1602159.78 at present.
Maxim Group took its bluebird bio Inc. [BLUE] rating to the equivalent of a Hold from a Buy,in a research note dated December 09, 2020. Other analysts also revised their coverage, with Maxim Group’s analysts downgrading the shares from “a Buy” rating to “a Hold” rating in a research note to investors issued in early December. Meanwhile, Berenberg had launched its coverage on BLUE with “Buy”, in a research note produced for clients November 11, 2020. In addition, there was a downgrade from Stifel on November 05, 2020. The rater changed BLUE from “a Buy” to “a Hold”.
Is bluebird bio Inc. [NASDAQ:BLUE] a Good Buy Right Now?
It should be noted that BLUE technical indicators for short, intermediate as well as long term progress have placed an overall average of 56% as Sell. The average signal changed from 100% Sell in the last week and compares with 100% Sell in the past month. Data from bluebird bio Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 1.08 million shares in the past 20 days and the short term average signal indicates a 50% Sell. In the last 50 days, the average trading volume was 1.18 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 100% Sell and the 100-day average volume stands at 0.91 million shares.
BLUE Price Performance
On Wall Street, bluebird bio Inc. [NASDAQ:BLUE] finished Friday’s session up 0.37% at $48.54. The stock went up to $49.54 at the same session while its lowest single day price was $47.28. In the last five days, it saw a rise of about 12.18%, bluebird bio Inc. shares gained by almost 12.18% since the beginning of the year. However, the share price has dropped to as low as -51.15% below its one year high. On 01/08/21, the company shares recorded $49.54, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $42.85. The company’s shares have declined by -46.65% in the past year. The 50-day SMA achieved is $46.15 while the 200-day SMA is $55.35. Volume dropped to 0.9 million from 1.01 million in the previous session.
BLUE Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 47.37 level, and in case of violation of this particular level, it will cause more drop to 46.19 level. On the upper level, 50.71 is still the key resistance. The stock may increase to the subsequent resistance at 49.63. The Relative Strength Index (RSI) pinned on the 14-day chart is 63.25, implying a neutral technical stance while the MACD stands at 1.79, meaning price will increase in the next trading period. Percent R indicator moved to 14.95%, implying bullish price movement. Stochastic %K at 73.47% suggest holding the stock.
What is the short interest in bluebird bio Inc.?
Short interest in the bluebird bio Inc. stock has plunged, decreasing by -0.12 million shares to total 6.95 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.83 million, data from Yahoo Finance shows. The increase of 1.73% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 15.24% of the overall float for the stock.
bluebird bio Inc.’s Biggest Shareholders: Who Owns bluebird bio Inc. [BLUE]?
Filings by Capital Research & Management Co showed that the firm now holds a total of 8,099,325 shares or roughly 12.20% of the outstanding BLUE shares. This means their shares have increased by 4,554 from the 8,099,325 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Wellington Management Co. LLP updated stake is worth $317,987,088. Details in the latest 13F filings reveal that The Vanguard Group, Inc. acquired their 3.76% stake valued at $274,514,172 while Capital Research & Management Co added theirs at $153,060,331. During the last quarter, The Vanguard Group, Inc. raised 225,761 of its shares in bluebird bio Inc. while Capital Research & Management Co bought 759 shares. The BlackRock Fund Advisors’s holdings currently number 3,262,701 shares at $158371506.54. According to the firm’s last 13F report, Sands Capital Management LLC shares in the company at filing stood at 3,195,715 shares, roughly $140,899,074.
BLUE Earnings Forecast For The Current Quarter
bluebird bio Inc. [BLUE] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $15.85M and an earnings per share of -$2.9 for Dec 2020. Looking further ahead, the company is expected to report revenue of $18.73M at an EPS of -$2.99 for Mar 2021. The estimates represent upside of -44.70% and -12.10% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
BLUE Earnings Estimates For The Current Year
For the financial year, bluebird bio Inc. [NASDAQ:BLUE] is expected to bring in revenue of $260.36M. The returns are nearly $215.69 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -9.89, higher than that of FY19 by $4.42. Estimates put this year’s earnings growth at 30.90%, -12.10% for the next, and at an annual -32.90% over the next 5-year period. As for sales, forecasts are for an increase of 482.80% in the current fiscal year and a further -44.70% over the following year.
What are analyst thoughts on bluebird bio Inc.?
Looking forward to the bluebird bio Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for bluebird bio Inc. stock at $80.00 within the next 12 months, which represents almost 39.32 per cent growth from its previous closing price of $48.54. The highest analysts’ target for bluebird bio Inc. stock projections is $146.00 and the lowest one is $48.00. Still, 24 analysts sharing their consensus rating for BLUE stock in 2021 agree that it is an Overweight.